Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
Guselkumab every 8 weeks led to consistent improvements through week 24 in joint, skin, PRO and composite outcomes versus placebo across diverse baseline-defined subgroups of TNFi-IR patients with PsA. Response rates increased or were durable through week 48 within most subgroups.
Authors
- Philipp Sewerin (ORCID: https://orcid.org/0000-0001-8465-6207)
- F. Lavie (ORCID: https://orcid.org/0000-0002-5213-257X)
- Michela Efficace
- Miriam Zimmermann (ORCID: https://orcid.org/0000-0001-6063-3000)
- Iain B. McInnes (ORCID: https://orcid.org/0000-0002-6462-4280)
- Laura C. Coates (ORCID: https://orcid.org/0000-0002-4756-663X)
- Mohamed Sharaf (ORCID: https://orcid.org/0009-0003-9847-2996)
Institutions
- Johnson & Johnson (United States) (US)
- Nuffield Orthopaedic Centre (GB)
- University of Oxford (GB)
- Janssen (France) (FR)
- Rheumazentrum Ruhrgebiet (DE)
- Johnson & Johnson (France) (FR)
- Janssen (Switzerland) (CH)
- Janssen (Italy) (IT)
- University of Glasgow (GB)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- RMD Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004494
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Research and Development